Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Terada, Yoshiki ^a   Nakamae, Hirohisa ^a   Aimoto, Ran ^a   Kanashima, Hiroshi ^b   Sakamoto, Erina ^b   Aimoto, Mizuki ^a   Inoue, Eri ^a   Koh, Hideo ^a   Nakane, Takahiko ^a   Takeoka, Yasunobu ^a   Ohsawa, Masahiko ^a   Koh, Ki Ryang ^a   Yamane, Takahisa ^a   Nakao, Yoshitaka ^c   Ohta, Kensuke ^d   Mugitani, Atsuko ^e   Teshima, Hirofumi ^b   Hino, Masayuki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c Wakakoukai Hospital   (Japan)

^d SAISEIKAI NAKATSU HOSPITAL   (Japan)

^e Fuchu Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADULT; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; CANCER STAGING; DISEASE FREE SURVIVAL; DOSE RESPONSE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; NEOPLASM STAGING; PREDNISOLONE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 70349309776     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-116     Document Type: Article

References (22)

1. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. RI Fisher ER Gaynor S Dahlberg MM Oken TM Grogan EM Mize JH Glick CA Coltman Jr TP Miller, N Engl J Med 1993 328 1002 6 10.1056/NEJM199304083281404 7680764
2. A predictive model for aggressive non-Hodgkin's lymphoma. International Non-Hodgkin's Lymphoma Prognostic Factors Project, N Engl J Med 1993 329 987 94 10.1056/NEJM199309303291402 8141877
3. Dose intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. R Epelbaum N Haim M Ben-Shahar Y Ron Y Cohen, Isr J Med Sci 1990 24 533 8
4. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. LW Kwak J Halpern RA Olshen SJ Horning, J Clin Oncol 1990 8 963 77 2348230
5. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. R Epelbaum D Faraggi Y Ben-Arie M Ben-Shahar N Haim Y Ron E Robinson Y Cohen, Cancer 1990 66 1124 9 10.1002/1097- 0142(19900915)66:6<1124::AID-CNCR28206606083.0.CO;2-T 2205353
6. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol: The GELA (Groupe d'Etude des Lymphomes de l'Adulte). E Lepage C Gisselbrecht C Haioun C Sebban H Tilly A Bosly P Morel R Herbrecht F Reyes B Coiffier, Ann Oncol 1993 4 651 6 7694634
7. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. A Bosly D Bron A Van Hoof R De Bock Z Berneman A Ferrant L Kaufman M Dauwe G Verhoef, Ann Hematol 2008 87 277 83 10.1007/s00277-007-0399-y 17952688
8. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. B Coiffier E Lepage J Briere R Herbrecht H Tilly R Bouabdallah P Morel E Van Den Neste G Salles P Gaulard F Reyes P Lederlin C Gisselbrecht, N Engl J Med 2002 346 235 42 10.1056/NEJMoa011795 11807147
9. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. M Pfreundschuh L Trumper A Osterborg R Pettengell M Trneny K Imrie D Ma D Gill J Walewski PL Zinzani R Stahel S Kvaloy O Shpilberg U Jaeger M Hansen T Lehtinen A Lopez-Guillermo C Corrado A Scheliga N Milpied M Mendila M Rashford E Kuhnt M Loeffler MabThera International Trial Group, Lancet Oncology 2006 7 379 91 10.1016/S1470-2045(06)70664-7 16648042
10. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. A Demidem T Lam S Alas K Hariharan N Hanna B Banavida, Cancer Biother Radiopharm 1997 12 177 186 10.1089/cbr.1997.12.177 10851464
11. Pathology and genetics: neoplasms of the hematopoietic and lymphoid tissues. ES Jaffe NL Harris J Vardiman H Stein, World Health Organization Classification of Tumours Lyon: IARC Press, Kleihues P, Sobin LH, 2001 237 53
12. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. NL Harris ES Jaffe H Stein PM Banks JK Chan ML Cleary G Delsol C De Wolf-Peeters B Falini KC Gatter, Blood 1994 84 1361 92 8068936
13. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. EM McKelvey JA Gottlieb HE Wilson A Haut RW Talley R Stephens M Lane JF Gamble SE Jones PN Grozea J Gutterman C Coltman TE Moon, Cancer 1976 38 1484 93 10.1002/1097-0142(197610)38:4<1484::AID-CNCR28203804073.0.CO;2-I 791473
14. -2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. TJ Smith J Khatcheressian GH Lyman H Ozer JO Armitage L Balducci Charles L Bennett Scott B Cantor Jeffrey Crawford Scott J Cross George Demetri Christopher E Desch Philip A Pizzo Charles A Schiffer Lee Schwartzberg Mark R Somerfield George Somlo James C Wade James L Wade Rodger J Winn Antoinette J Wozniak Antonio C Wolff, J Clin Oncol 2006 1 3187 205 10.1200/JCO.2006.06.4451 (Pubitemid 46638957)
15. Regression models and life tables (with discussion). DR Cox, J R Stat Soc B 1972 34 187 220
16. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: Comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. KW Lee DY Kim T Yun DW Kim TY Kim SS Yoon DS Heo YJ Bang S Park BK Kim NK Kim, Cancer 2003 98 2651 6 10.1002/cncr.11846 14669285
17. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. MI Vega S Huerta-Yepaz H Garban A Jazirehi C Emmanouilides B Bonavida, Oncogene 2004 23 3530 40 10.1038/sj.onc.1207336 15077178
18. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. S Alas B Bonavida, Cancer Res 2001 61 5137 44 11431352
19. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. GH Lyman DC Dale J Friedberg J Crawford RI Fisher, Journal of Clin Oncol 2004 22 4302 11 10.1200/JCO.2004.03. 213 (Pubitemid 41185151)
20. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. MS Aapro DA Cameron R Pettengell J Bohlius J Crawford M Ellis N Kearney GH Lyman VC Tjan-Heijnen J Walewski DC Weber C Zielinski European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party, Eur J Cancer 2006 42 2433 53 10.1016/j.ejca.2006.05.002 16750358
21. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Ruth Pettengell André Bosly Thomas D Szucs Christian Jackisch Robert Leonard Robert Paridaens Manuel Constenla Matthias Schwenkglenks, British Journal of Haematology 2009 144 677 685 10.1111/j.1365-2141.2008.07514.x 19055662
22. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). M Pfreundschuh J Schubert M Ziepert R Schmits M Mohren E Lengfelder M Reiser C Nickenig M Clemens N Peter C Bokemeyer H Eimermacher A Ho M Hoffmann R Mertelsmann L Trumper L Balleisen R Liersch B Metzner F Hartmann B Glass V Poeschel N Schmitz C Ruebe AC Feller M Loeffler German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL), Lancet Oncol 2008 9 105 16 10.1016/S1470-2045(08)70002-0 18226581